STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer
Open Access
- 12 September 2017
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (49) , 85997-86010
Abstract
STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancerKeywords
This publication has 68 references indexed in Scilit:
- JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like CellsCancer Research, 2013
- Overexpression of signal transducer and activator of transcription (STAT-3 and STAT-5) transcription factors and alteration of suppressor of cytokine signaling (SOCS-1) protein in prostate cancerJournal of Receptors and Signal Transduction, 2012
- Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trialThe Lancet, 2011
- MST1 Is a Multifunctional Caspase-Independent Inhibitor of Androgenic SignalingCancer Research, 2011
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitorsBlood, 2011
- The two faces of Janus kinases and their respective STATs in mammary gland development and cancerJournal of Carcinogenesis, 2011
- Transcription Factor Stat3 Stimulates Metastatic Behavior of Human Prostate Cancer Cells in Vivo, whereas Stat5b Has a Preferential Role in the Promotion of Prostate Cancer Cell Viability and Tumor GrowthThe American Journal of Pathology, 2010
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Silibinin Suppresses Growth of Human Prostate Carcinoma PC-3 Orthotopic Xenograft via Activation of Extracellular Signal-Regulated Kinase 1/2 and Inhibition of Signal Transducers and Activators of Transcription SignalingClinical Cancer Research, 2009
- Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancerBritish Journal of Cancer, 2007